Transcriptional landscape of pleural mesothelioma patients in relation to NF2 gene mutational status

Our plain-English summary of Transcriptional landscape of pleural mesothelioma patients in relation to NF2 gene mutational status, by C. Orozco-Castaño, A. Mejía-Garcia, H.M. Tsao, et al (Journal of the Egyptian National Cancer Institute, 2025).

The study

• Authors: C. Orozco-Castaño, A. Mejía-Garcia, H.M. Tsao, D.A. Bonilla, C. Carvajal-Fierro, R. Bruges-Maya, A. Combita, R. Parra-Medina
• Journal: Journal of the Egyptian National Cancer Institute
• Published: 2025;37(1):25
• Cited by: 4 articles, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Background: Pleural mesothelioma (PM) is an aggressive cancer with poor prognosis, often driven by asbestos exposure. Mutations in the NF2 gene, a key regulator of the Hippo signaling pathway, are frequently observed in PM. However, their impact on tumor biology, immune infiltration, cytokine signaling, and therapeutic response remains poorly understood.

Methods: Using data from The Cancer Genome Atlas, we analyzed 82 PM cases to assess the prevalence and consequences of NF2 mutations. Logistic regression was used to evaluate associations with clinical variables, while transcriptomic differences were examined through differential expression and functional enrichment analyses. Immune and stromal infiltration were inferred via the xCell algorithm, cytokine signaling analyzed with Cytosig, and chemotherapeutic sensitivity predicted using the pRRophetic R package. Single-cell RNA sequencing data provided further insights into transcriptional patterns in NF2-mutated tumors.

Results: NF2 mutations were present in 22% of cases, with no significant correlations to histological subtype, stage, or age. NF2-mutated tumors exhibited increased infiltration of basophils, naïve B cells, and pericytes, along with altered cytokine profiles, including NRG1, TGFB3, and reduced FGF2. Differentially expressed genes, such as MYL7 and HOXA11, were linked to poorer survival. Chemotherapy modeling indicated higher sensitivity to camptothecin and vinblastine in NF2-mutated tumors.

Conclusions: NF2 mutations influence the tumor microenvironment, transcriptional landscape, and predicted therapeutic response in PM, underscoring their potential as prognostic biomarkers. These findings support tailored therapeutic strategies targeting NF2-related pathways, including Hippo signaling and cytokine modulation.

© 2025. The Author(s).

In plain English

This study was a computer-based analysis of public genetic and gene-activity data on pleural mesothelioma from The Cancer Genome Atlas (TCGA). It compared tumors with and without mutations in the NF2 gene. The authors reported NF2 mutations in 20 out of 82 patients. The clinical features they evaluated showed no significant association with NF2 mutation status. Overall survival did not differ significantly between patients with and without NF2 mutations (p = 0.4992). In NF2-mutated tumors, estimated levels of basophils, naïve B cells and pericytes were higher. Predicted NRG1, TWEAK and TGFB3 levels were higher and FGF2 lower. Higher expression of six genes more active in NF2-mutated tumors, including MYL7 and HOXA11, was associated with poorer survival. Models built from gene expression, not observed treatment, predicted modestly greater sensitivity to camptothecin and vinblastine in NF2-mutated tumors. They predicted greater sensitivity to Akt Inhibitor VIII in NF2 wild-type tumors. Occupational asbestos exposure was listed among the variables tested, but the article text gives no separate result for it. The authors concluded that their findings point to the potential of NF2 mutations as prognostic biomarkers. They noted the small sample, cross-sectional data and the need for validation.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Computational secondary analysis of publicly available bulk RNA-seq, mutation and clinical data (TCGA MESO cohort), plus analysis of a public single-cell RNA-seq dataset
• Who was studied: 82 pleural mesothelioma patients in the TCGA MESO cohort: 20 NF2-mutated and 62 NF2 wild-type. Also a separate single-cell dataset (GSE190597) of 13 primary tumors (nine epithelioid, two biphasic, two sarcomatoid) with 84,526 cells. Location and dates of patient collection are not given.
• Exposure: The main comparison was tumor NF2 gene mutation status (mutated vs wild-type). Occupational asbestos exposure was named in the methods as one of the clinical variables tested against NF2 status. No fiber types, products or doses are described.
• Main results:
  • NF2 mutations were found in 20 of the 82 TCGA pleural mesothelioma patients.
  • The clinicopathological features evaluated showed no significant association with NF2 mutation status. These included demographic factors, detection methods, primary diagnosis, tumor stage and cancer status.
  • Overall survival did not differ significantly by NF2 mutation status (p = 0.4992) or by NF2 expression level (p = 0.7671).
  • NF2 methylation was associated with survival (p = 0.02949). In the Results section, patients with lower methylation (at or below 0.2396) had improved survival compared with those above 0.2396. A later passage states the opposite direction.
  • Of the top 40 genes more active in NF2-mutated tumors, 13 were associated with reduced overall survival in univariate Cox analysis, and five kept significance in multivariate analysis. In Kaplan–Meier analysis, higher expression of six genes was associated with decreased overall survival: MYL7, HOXA11, ZIC2, IGFL3, ISL1 and VSX1.
  • Of 64 cell types estimated by xCell, basophils, naïve B cells and pericytes were significantly increased in NF2-mutated tumors compared with wild-type tumors.
  • Cytosig analysis of 64 molecules found significant differences in four. NF2-mutated patients had higher NRG1, TWEAK and TGFB3 and lower FGF2 than NF2 wild-type patients.
  • Predicted from gene expression: NF2-mutated patients had modestly but significantly higher sensitivity to camptothecin (p = 0.0412) and vinblastine (p = 0.0446). NF2 wild-type patients had higher predicted sensitivity to Akt Inhibitor VIII (p = 0.0322).
  • In the single-cell data, NF2 was expressed in 0 to 16% of each patient's malignant cells.
• The authors' conclusion: The authors concluded that NF2 mutations influence the tumor microenvironment, gene activity and predicted treatment response in pleural mesothelioma, and that this points to their potential as prognostic biomarkers. In the discussion they also wrote that the study underscores the significance of NF2 mutations as biomarkers for disease progression and therapeutic response.
• Limitations the authors state:
  • The public datasets may not fully represent the genetic diversity of pleural mesothelioma across populations.
  • The TCGA cohort is small, especially the NF2-mutated subset, which limits generalizability.
  • The data are cross-sectional, so causal inferences about NF2 mutations and clinical outcomes cannot be drawn.
  • The immune and stromal cell estimates were computational and need experimental validation.
  • The chemotherapy response predictions require clinical validation.
  • The limited number of non-epithelioid cases may have reduced the ability to detect associations with histological subtype.

Topics

The National Library of Medicine indexes this study under subjects our site covers: Mesothelioma.

Medical terms in this study, explained in our Lexicon: Pleural Mesothelioma, Prognosis, Asbestos Exposure, Hippo Signaling Pathway, Cytokine, Histological Subtype, Chemotherapy, Tumor Microenvironment.

Related studies

• Genetic Landscape of a Pleural Mesothelioma in a Child Affected by NF2-Related Schwannomatosis — M. Ognibene, G. Piccolo, et al. (2025)
• Gene therapy for diffuse pleural mesotheliomas in preclinical models by concurrent expression of NF2 and SuperHippo — R. Zhu, X. Liu, et al. (2024)
• Spatial Landscape of Malignant Pleural and Peritoneal Mesothelioma Tumor Immune Microenvironments — X. Ma, D. Lembersky, et al. (2024)
• Mutational analysis of hedgehog signaling pathway genes in human malignant mesothelioma — C.B. Lim, C.M. Prêle, et al. (2013)
• Mutational Profiling of Driver Tumor Suppressor and Oncogenic Genes in Brazilian Malignant Pleural Mesotheliomas — N.C. Campanella, E.C. Silva, et al. (2020)
• Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma — S. Brich, F. Bozzi, et al. (2020)

Browse return to medical research.